Israel - English - Ministry of Health

sanofi - aventis israel ltd - lenograstim 33.6 miu/ml - lyophilized powder for injection - lenograstim - - reduction in duration of neutropenia and associated complications in patients undergoing bone marrow transplantation or cytotoxic chemotherapy associated with a febrile neutropenia. - autologous mobilization of peripheral blood progenitor cells. as an adjunct to allogenic mobilization of peripheral blood progenitor cells (pbpcs).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chugai pharma uk ltd - lenograstim - powder and solvent for solution for injection - 13.4mega unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chugai pharma uk ltd - lenograstim - powder and solvent for solution for injection - 33.6mega unit

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

chugai pharmaceutical co., ltd. - lenograstim(genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

chugai pharmaceutical co., ltd. - lenograstim(genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

chugai pharmaceutical co., ltd. - lenograstim(genetical recombination) - injection

Ireland - English - HPRA (Health Products Regulatory Authority)

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 13 million iu/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 34 million iu/ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - lenograstim - injection, powder, for solution - 263 mcg/ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - rhug-csf(lenograstim) -